Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott suspends distribution of HIV I/II assay in overseas markets due to false negatives.

This article was originally published in The Gray Sheet

Executive Summary

ABBOTT SUSPENDS DISTRIBUTION OF IMx HIV-I/HIV-II 3RD GENERATION PLUS HIV assay sold in Europe, Australia, South Africa, Latin America and Asia. Germany-based Abbott Diagnostika GmbH stopped distributing the 3rd Generation Plus test on March 25 after learning that the assay had failed to detect four confirmed positive samples in Europe. The test is not sold in the U.S., Canada or Japan.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel